Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Baxter
Chinese Patent Office
Deloitte
Express Scripts
Mallinckrodt
Merck
Queensland Health
Cantor Fitzgerald

Generated: December 10, 2017

DrugPatentWatch Database Preview

Patents Expiring in September 2017

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Purdue Pharma LpBUTRANSbuprenorphineFILM, EXTENDED RELEASE;TRANSDERMAL021306-005Jun 30, 2014RXYesNo► Subscribe► Subscribe► SubscribeMANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
Purdue Pharma LpBUTRANSbuprenorphineFILM, EXTENDED RELEASE;TRANSDERMAL021306-003Jun 30, 2010RXYesYes► Subscribe► Subscribe► SubscribeMANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
Purdue Pharma LpBUTRANSbuprenorphineFILM, EXTENDED RELEASE;TRANSDERMAL021306-001Jun 30, 2010RXYesNo► Subscribe► Subscribe► SubscribeTHE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
Purdue Pharma LpBUTRANSbuprenorphineFILM, EXTENDED RELEASE;TRANSDERMAL021306-001Jun 30, 2010RXYesNo► Subscribe► Subscribe► SubscribeTHE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
Purdue Pharma LpBUTRANSbuprenorphineFILM, EXTENDED RELEASE;TRANSDERMAL021306-003Jun 30, 2010RXYesYes► Subscribe► Subscribe► SubscribeTHE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
Purdue Pharma LpBUTRANSbuprenorphineFILM, EXTENDED RELEASE;TRANSDERMAL021306-004Jul 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeMANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
Purdue Pharma LpBUTRANSbuprenorphineFILM, EXTENDED RELEASE;TRANSDERMAL021306-002Jun 30, 2010RXYesNo► Subscribe► Subscribe► SubscribeMANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
Purdue Pharma LpBUTRANSbuprenorphineFILM, EXTENDED RELEASE;TRANSDERMAL021306-001Jun 30, 2010RXYesNo► Subscribe► Subscribe► SubscribeMANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
Purdue Pharma LpBUTRANSbuprenorphineFILM, EXTENDED RELEASE;TRANSDERMAL021306-003Jun 30, 2010RXYesYes► Subscribe► Subscribe► SubscribeTHE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
Purdue Pharma LpBUTRANSbuprenorphineFILM, EXTENDED RELEASE;TRANSDERMAL021306-004Jul 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeMANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Johnson and Johnson
Baxter
Harvard Business School
Farmers Insurance
Federal Trade Commission
Chubb
Boehringer Ingelheim
Cipla
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot